2型糖尿病的二肽基肽酶-4抑制剂与磺脲类药物：是友还是敌？ - Suppr

Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?

作者信息

Yabe Daisuke, Seino Yutaka

机构信息

Center for Diabetes, Endocrinology and Metabolism Osaka Japan ; Center for Metabolism and Clinical Nutrition Kansai Electric Power Hospital Osaka Japan ; Division of Molecular and Metabolic Medicine Kobe University Graduate School of Medicine Kobe Japan.

Center for Diabetes, Endocrinology and Metabolism Osaka Japan.

出版信息

J Diabetes Investig. 2014 Sep;5(5):475-7. doi: 10.1111/jdi.12229.

DOI:10.1111/jdi.12229

PMID:25411611

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4188101/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f81d/4188101/97012c9c9f4c/jdi-5-475-g1.jpg

相似文献

Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?

J Diabetes Investig. 2014 Sep;5(5):475-7. doi: 10.1111/jdi.12229.

Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke.

Diab Vasc Dis Res. 2015 Nov;12(6):463-6. doi: 10.1177/1479164115597867. Epub 2015 Aug 21.

[Severe hypoglycemia by combination therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and sulfonylureas].

Nihon Rinsho. 2011 May;69(5):907-11.

Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.

Adv Ther. 2012 Sep;29(9):736-46. doi: 10.1007/s12325-012-0045-5. Epub 2012 Aug 24.

Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.

Metabolism. 2009 Mar;58(3):379-86. doi: 10.1016/j.metabol.2008.10.012.

Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.

J Cardiovasc Nurs. 2016 May-Jun;31(3):274-83. doi: 10.1097/JCN.0000000000000245.

Effect of dipeptidyl peptidase-4 inhibitor in patients undergoing bypass surgery.

Asian Cardiovasc Thorac Ann. 2016 Nov;24(9):863-867. doi: 10.1177/0218492316677384. Epub 2016 Oct 26.

Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.

Diabet Med. 2014 Nov;31(11):1293-300. doi: 10.1111/dme.12561.

Metformin in Combination With Dipeptidyl Peptidase-4 Inhibitors or Sulfonylureas in The Treatment of Type 2 Diabetes: Clinical And Economic Impact.

Value Health. 2014 Nov;17(7):A339-40. doi: 10.1016/j.jval.2014.08.669. Epub 2014 Oct 26.

Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.

Clin Exp Pharmacol Physiol. 2015 Oct;42(10):999-1024. doi: 10.1111/1440-1681.12455.

引用本文的文献

Evolving incretin-based therapies in Japan: optimizing treatment strategies for diverse clinical and socioeconomical profiles in type 2 diabetes.

Diabetol Int. 2025 May 15;16(3):457-468. doi: 10.1007/s13340-025-00818-w. eCollection 2025 Jul.

Role of diet and exercise in aging, Alzheimer's disease, and other chronic diseases.

Ageing Res Rev. 2023 Nov;91:102091. doi: 10.1016/j.arr.2023.102091. Epub 2023 Oct 11.

Incretin and Pancreatic β-Cell Function in Patients with Type 2 Diabetes.

Endocrinol Metab (Seoul). 2023 Feb;38(1):1-9. doi: 10.3803/EnM.2023.103. Epub 2023 Feb 13.

Changes in prescription patterns and doses of oral antidiabetic drugs in Japanese patients with type 2 diabetes (JDDM70).

J Diabetes Investig. 2023 Jan;14(1):75-80. doi: 10.1111/jdi.13922. Epub 2022 Oct 21.

Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.

Adv Ther. 2022 Apr;39(4):1642-1658. doi: 10.1007/s12325-021-02038-5. Epub 2022 Feb 9.

Current status of oral antidiabetic drug prescribing patterns based on the body mass index for Japanese type 2 diabetes mellitus patients and yearly changes in diabetologists' prescribing patterns from 2002 to 2019 (JDDM61).

J Diabetes Investig. 2022 Jan;13(1):65-73. doi: 10.1111/jdi.13621. Epub 2021 Jul 30.

Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).

Diabetol Int. 2020 Feb 14;11(3):274-282. doi: 10.1007/s13340-020-00426-w. eCollection 2020 Jul.

Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.

Adv Ther. 2020 Mar;37(3):1065-1086. doi: 10.1007/s12325-019-01189-w. Epub 2019 Dec 23.

Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database.

Diabetol Metab Syndr. 2019 Nov 1;11:90. doi: 10.1186/s13098-019-0486-y. eCollection 2019.

Fusion pore regulation by cAMP/Epac2 controls cargo release during insulin exocytosis.

Elife. 2019 May 20;8:e41711. doi: 10.7554/eLife.41711.

本文引用的文献

Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.

J Diabetes Investig. 2013 Mar 18;4(2):108-30. doi: 10.1111/jdi.12065.

Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A.

Sci Signal. 2013 Oct 22;6(298):ra94. doi: 10.1126/scisignal.2004581.

Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner.

Diabetes. 2011 Jan;60(1):218-26. doi: 10.2337/db10-0021. Epub 2010 Oct 26.

The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs.

Science. 2009 Jul 31;325(5940):607-10. doi: 10.1126/science.1172256.

Metabolic inhibition impairs ATP-sensitive K+ channel block by sulfonylurea in pancreatic beta-cells.

Am J Physiol. 1998 Jan;274(1):E38-44. doi: 10.1152/ajpendo.1998.274.1.E38.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献